Your browser is no longer supported. Please, upgrade your browser.
Settings
PSTV Plus Therapeutics, Inc. daily Stock Chart
PSTV [NASD]
Plus Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand0.12M Perf Week95.36%
Market Cap0.91M Forward P/E- EPS next Y-29.75 Insider Trans- Shs Float- Perf Month-33.22%
Income-13.90M PEG- EPS next Q-11.00 Inst Own5.30% Short Float- Perf Quarter-45.74%
Sales6.40M P/S0.14 EPS this Y- Inst Trans45.87% Short Ratio0.69 Perf Half Y-39.36%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-69.42%
Cash/sh37.50 P/C0.20 EPS next 5Y- ROE- 52W Range3.80 - 37.50 Perf YTD-47.72%
Dividend- P/FCF- EPS past 5Y- ROI-65.50% 52W High-79.79% Beta2.36
Dividend %- Quick Ratio- Sales past 5Y-11.40% Gross Margin61.90% 52W Low99.47% ATR2.26
Employees37 Current Ratio0.40 Sales Q/Q-81.30% Oper. Margin- RSI (14)47.76 Volatility52.49% 27.49%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.65 Prev Close7.30
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume330.97K Price7.58
Recom- SMA20-4.10% SMA50-27.26% SMA200-44.23% Volume213,526 Change3.84%
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.